CTRI/2021/08/035884
Not yet recruiting
Phase 4
A prospective, randomized, triple-blind comparative study of ropivacaine with bupivacaine plus lidocaine mixtures used in peribulbar blocks for cataract surgery - RVB
Gayatri vidya parishad Institute of health care and medical technology0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: H251- Age-related nuclear cataractHealth Condition 2: O- Medical and Surgical
- Sponsor
- Gayatri vidya parishad Institute of health care and medical technology
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria for our study consist of both male and female
- •patients with an age range between 40 and 80 years and are of
- •American Society of Anesthesiologists (ASA) physical status grades
- •I and II attending our medical college hospital for elective cataract
Exclusion Criteria
- •The exclusion criteria for our study include patients with known
- •allergy to study drugs, those refusing the regional block, those on
- •anticoagulant therapy, high myopia (axial length of eyeball \> 28 mm),
- •previous ophthalmic surgery such as buckling surgery, glaucoma,
- •posterior staphyloma, ocular infection, orbital anomaly, mental
- •retardation, uncontrolled hypertension \& diabetes mellitus, and
- •chronic obstructive pulmonary disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Ropivacaine-dexmedetomidine versus ropivacaine alone in peribulbar blocksCTRI/2020/03/023951Gayatri vidya parishad Institute of health care and medical technology
Completed
Not Applicable
A clinical study to assess the safety and effectiveness of collagen-containing test products in healthy adult Human subjectsCTRI/2022/11/047566Bright LifeCare Private Limited56
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220